Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised open-label presurgical study of AZD9833 with or without fulvestrant in early estrogen receptor-positive breast cancer
2020-001079-33Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camizestrant in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Change in estrogen receptor expression. Status: unknown.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-001079-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001079-33.